Track topics on Twitter Track topics that are important to you
75% of treated MS patients showed no disability progression at five years post-treatment.
Original Article: Mavenclad real-world data shows sustained efficacyNEXT ARTICLE
Multiple Sclerosis MS
Multiple sclerosis (MS) is the most common disabling neurological condition affecting 100,000 young adults in the UK. The condition results from autoimmune damage to myelin, causing interference in nerve signaling. Symptoms experienced depend on the pa...